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CONCISE COMMUNICATION
Global population-level association between herpes
simplex virus 2 prevalence and HIV prevalence
Silva P. Kouyoumjiana, Marieke Heijnena,c, Karima Chaabnaa,c,
Ghina R. Mumtaza,b, Ryosuke Omoria,c,d,e, Peter Vickermanf
and Laith J. Abu-Raddadc
Background: Our objective was to assess the population-level association between
herpes simplex virus 2 (HSV-2) and HIV prevalence.
Methods: Reports of HSV-2 and HIV prevalence were systematically reviewed and
synthesized following PRISMA guidelines. Spearman rank correlation ( ) was used to
assess correlations. Risk ratios (RRHSV-2/HIV) and odds ratios (ORHSV-2/HIV) were used to
assess HSV-2/HIV epidemiologic overlap. DerSimonian–Laird random-effects meta-
analyses were conducted.
Results: In total, 939 matched HSV-2/HIV prevalence measures were identified from
77 countries. HSV-2 prevalence was consistently higher than HIV prevalence. Strong
HSV-2/HIV prevalence association was found for all data ( ¼0.6, P<0.001), all data
excluding people who inject drugs (PWID) and children ( ¼0.7, P<0.001), female sex
workers ( ¼0.5, P<0.001), and MSM ( ¼0.7, P<0.001). No association was found
for PWID ( ¼0.2, P¼0.222) and children ( ¼0.3, P¼0.082). A threshold effect was
apparent where HIV prevalence was limited at HSV-2 prevalence less than 20%, but
grew steadily with HSV-2 prevalence for HSV-2 prevalence greater than 20%. The
overall pooled mean RRHSV-2/HIV was 5.0 (95% CI 4.7–5.3) and ORHSV-2/HIV was 9.0
(95% CI 8.4–9.7). The RRHSV-2/HIV and ORHSV-2/HIV showed similar patterns that
conveyed inferences about HSV-2 and HIV epidemiology.
Conclusion: HSV-2 and HIV prevalence are strongly associated. HSV-2 prevalence can
be used as a proxy ‘biomarker’ of HIV epidemic potential, acting as a ‘temperature
scale’ of the intensity of sexual risk behavior that drive HIV transmission. HSV-2
prevalence can be used to identify populations and/or sexual networks at high-risk
of future HIV expansion, and help prioritization, optimization, and resource allocation
of cost-effective prevention interventions.
Copyright  2018 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
The ability to predict HIV epidemics and their scale is
important to inform response [1]. This ability is of
particular value in regions where HIV epidemics are
emerging, such as in the Middle East and North Africa
(MENA) [2], or in high-risk populations, where
epidemics can emerge suddenly and rapidly, such
as amongst MSM [3], or people who inject drugs
(PWID) [4].
Self-reported sexual behavior data may provide one
approach for understanding sexual networks and assessing
HIVepidemic potential, but such data suffers from multiple
limitations [5,6]. Self-reported data are subject to biases,
and as they are egocentric, cannot capture the complexity
of sexual-network structures [5,7]. Network structure,
however, plays a critical role in determining the risk of
exposure to HIVand other sexually transmitted infections
(STIs) [6,8].
Mathematical modeling and empirical data have demon-
strated recently that hepatitis C virus (HCV) prevalence
can quantify the intensity of injecting risk behavior in
PWID, and can predict HIV epidemic potential in this
population [9–11]. This powerful concept of using the
prevalence of one infection as an objective ‘biomarker’ to
predict the prevalence of another infection, for infections
that share the same mode of transmission, opens novel
possibilities for understanding risk networks and the
overlapping epidemiology of infectious diseases.
It was proposed and demonstrated recently, through in-
silico simulations of HIVand herpes simplex virus type 2
(HSV-2) transmission in sexual networks, that HSV-2
prevalence could be used as a ‘summary collective
measure’ of the intensity of sexual risk behavior in a
sexual network, and can predict HIV epidemic potential
[5,6].
Against this background, we investigated the empirical
evidence for using HSV-2 prevalence as a ‘biomarker’ to
predict HIV epidemic potential in a given population.
We conducted a global systematic review of HSV-2 and
HIV prevalence within the same population. We further
conducted meta-analyses of HSV-2/HIV epidemio-
logic overlap, and assessed how this overlap varies by sex,
region, and subpopulation. This is to our knowledge the
first time in the literature that such an in-depth and
systematic analysis of this ecological association for
all world regions and for all different at-risk popula-
tions has been conducted and has quantified the
association using primary data. We thus provided
a comprehensive characterization of HSV-2/HIV
overlapping epidemiology that yielded profound
insights about HIV epidemiology and how sexual
networks drive STI transmission.
Methods
Data sources and search strategy
We systematically reviewed HSV-2/HIV prevalence data
as informed by Cochrane Collaboration Handbook for
Systematic Reviews [12] and reported findings following
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [13,14] (Text
S1 of Supplementary Information, http://links.lww.-
com/QAD/B268. We searched PubMed, Embase, the
abstract archives of the International AIDS Society (IAS)
and International Society for Sexually Transmitted
Diseases Research (ISSTDR) conferences, with no
language, geographic region, population, or publication
year restrictions. We searched PubMed and Embase using
a strategy with both free text and MeSH/Emtree headings
up to 12 October 2016 (Search criteria in Text S2 of
Supplementary Information). Additional data were
identified in several grey literature reports.
Study selection
Search results were imported into a reference manager,
Endnote X7, where duplicates were identified and
excluded. Titles and abstracts of remaining records were
screened for relevance by one author (S.P.K.). Full texts of
potentially relevant records were retrieved and assessed for
eligibility; and reference lists of all relevant articles were
screened for additional studies. Reports were included if
they presented primary data with serological measure-
ments of HSV-2 and HIV prevalence in the same
population; and, used a type-specific assay (based on
ELISA or western blot test) for HSV-2 diagnosis. Reports
were excluded if they included self-reported prevalence;
and, included only HSV-2/HIV-infected individuals, or
included individuals based on their infection status - such
as serodiscordant couples. Case studies, editorials,
commentaries, letters to editor, and review papers were
excluded, though bibliographies of reviews were screened
for potentially relevant sources.
The term ‘report’ was used to refer to the documents
(articles, conference abstracts, or country-level reports)
presenting results of a study [12]. The term ‘datapoint’ or
‘study’ refers to a measure of matched HSV-2/HIV
prevalence. Datapoints duplicated in more than one
report were included only once (using the more detailed
report). If two reports report the same study, the report
with the largest sample size was used. Outcomes in more
than one population/setting within a report were
included as separate datapoints.
Data extraction
Datapoints were extracted by one author (S.P.K.) using a
prepiloted data-extraction form and entered into a
computerized database. To ensure consistency, a random
sample (20%) of studies was checked by a second author
(K.C.). Extracted information included publication type,
study design, year(s) and location of data collection, study
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population, sampling method, sample size, proportion of
men/women, and number of individuals tested for, and
infected with, HSV-2/HIV. Any discrepancies were
settled by consensus or by contacting authors. Data from
abstracts were extracted from the English abstract directly
if not published as an article or if the full-text article was
not available. Data from articles in English and Spanish
were extracted from the full-texts - data from other
language publications were extracted from the English
abstract.
Plan of analysis
Populations were categorized based on the perceived level
of sexual risk behavior into: high-risk [female sex workers
(FSWs), clients of FSWs, and MSM), intermediate risk
(such as prisoners and STI-clinic attendees), and general
population (such as pregnant women and healthy adults).
A full list of population categories is included in Text S3
of Supplementary Information. For the regional analyses,
datapoints were categorized into the six divides: North
America, South/Latin America, Europe, MENA, Sub-
Saharan Africa (SSA), and Asia.
Descriptive analyses
We examined the ecological population-level association
between HSV-2/HIV prevalence using scatterplots for all
data, and for specific population categories. Spearman
rank correlation was used to assess the correlation
(expressed as ) and P values, with significance set at P
less than 0.05.
Measures of the epidemiologic overlap
We explored both the risk ratio (RR) and odds ratio
(OR) to quantify the epidemiological overlap between
HSV-2/HIV, as has been done recently for HCV/HIV
[10,11]. These two measures are closely related, but we
used both because of subtle mathematical intricacies, and
to provide description of the overlap using common
measures in the literature [15].
The HSV-2/HIV RR was defined as the ratio of the
prevalence (‘risk’) of HSV-2 to that of HIV in the same
population:
RRHSV2=HIV ¼
PHSV2
PHIV
:
Similarly, the HSV-2/HIV OR was defined as the ratio of
the odds of HSV-2 to that of HIV in the same population:
ORHSV2=HIV ¼
OddsHSV2
OddsHIV
¼ PHSV2
1 PHSV2
 
=
PHIV
1 PHIV
 
:
Histograms were used to assess the distribution of
loge RRð Þ and loge ORð Þ
Meta-analyses
Meta-analyses for RRHSV-2/HIV/ORHSV-2/HIV were
conducted by risk population, by subpopulation within
the high-risk group, and for men and women separately.
DerSimonian-Laird random-effects models were imple-
mented using inverse-variance weighting [16]. This type
of models assumes a normal distribution of true effect
sizes across studies, and as such accounts for both,
sampling variation and heterogeneity in effect size [17].
Meta-analyses excluded populations where the dominant
mode of HIV transmission is perceived not to be sexual
(PWID and children), studies with sample size less than
50, and studies with zero prevalence for both of HSV-2/
HIV. Cochran’s Q-test was used to assess evidence for
heterogeneity in effect size - a P value less than 0.1 was
considered significant [17,18]. I2 was computed to assess
the proportion of between-study variation that is because
of true differences in effect size [17]. Meta-analyses were
conducted for all regions combined, and for all regions
excluding SSA. SSA exclusion was because of the special
nature of the HIV epidemics in this region.
For datapoints where HIV prevalence was zero, a 0.5 case
number was added to allow for the computation of
RRHSV-2/HIV/ORHSV-2/HIV. A sensitivity analysis was
conducted by excluding all datapoints with zero HIV
prevalence - results were invariable.
All analyses were carried out using STATA version 13.0
[19] (StataCorp LP, College Station, Texas, USA).
Results
Search results
Figure 1 describes the study selection process, as per
PRISMA guidelines [13]. Records were identified
through PubMed (2403), Embase (3712), and conference
abstract archives (2554). After multiple screening levels,
386 reports were eligible and contributed 849 datapoints
on 756 829 participants from 77 countries, the majority
being from Asia and SSA (Fig. 1 and Table 1).
Descriptive analysis
Scatterplots of the association between HSV-2/HIV
prevalence are shown in Fig. 2. Strong and statistically
significant correlation was found for all datapoints ( =
0.6, P < 0.001; Fig. 2a), FSWs ( = 0.5, P < 0.001;
Fig. 2b), MSM ( = 0.7, P < 0.001; Fig. 2c), and people
who use but do not inject drugs ( = 0.7, P < 0.001;
Fig. 2d). However, the correlation was weak and not
statistically significant for PWID ( = 0.2, P = 0.222;
Fig. 2e) and children including orphans of HIV+
mothers ( = 0.3, P = 0.082; Fig. 2f). By excluding
all data points from nonsexual-transmission populations
(PWID and children), the correlation increased in
strength ( = 0.7, P < 0.001; Fig. 2g).
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HSV-2 prevalence was consistently higher than HIV
prevalence in all populations (Fig. 2a-d and g) apart from
PWID and children (Fig. 2e and F). From visual
inspection of Fig. 2, a threshold effect seems apparent
where HIV prevalence was very low or vanishing at HSV-
2 prevalence less than 20% or so, but growing steadily
with HSV-2 pre- valence for HSV-2 prevalence greater
than 20% (Fig. 2g). This effect seemed most pronounced
for FSWs (Fig. 2b).
Figure 2h and i present the loge RRð Þ and loge ORð Þ
distributions including all data points excluding PWID
and children. These figures suggest a roughly normal
distribution with a positive skew and a median of 1.6 for
1346 AIDS 2018, Vol 32 No 10
Fig. 1. Flow chart of included studies, adapted from Preferred Reporting Items for Systematic Reviews and Meta-Analyses
guidelines. Data from [13].
loge RRð Þ (RRHSV-2/HIV¼ 5), and a median of 2.2 for
loge ORð Þ (ORHSV-2/HIV¼ 9).
Measures of herpes simplex virus type 2/HIV
epidemiologic overlap
Table 1 and Table S1, http://links.lww.com/QAD/B268
of Supplementary Information show the pooled mean
RRHSV-2/HIV and ORHSV-2/HIV, respectively, by region
and globally, for all data points excluding PWID and
children.
Overall risk ratio and odds ratio
The overall RRHSV-2/HIV was 5 [95% confidence interval
(CI) 4.7–5.3], increasing to 7 (95% CI 6.4–7.6) when
SSA was excluded from the analysis (Table 1). The overall
ORHSV-2/HIV was 9 (95% CI 8.4–9.7), increasing to 13.6
(95% CI 12.2–15.2) with SSA exclusion (Table S1,
http://links.lww.com/QAD/B268). There was strong
evidence for heterogeneity with a P value 0.001 or less.
Most variation was because of heterogeneity in effect size
(that is RRHSV-2/HIV or ORHSV-2/HIV) across studies
rather than chance (I2> 90%).
Risk ratio and odds ratio by region
The RRHSV-2/HIV was the lowest in SSA at 3.4 (95% CI
3.1–3.6) and the highest in MENA at 23 (95% CI 8.8–
59.6). It was comparable in Asia and Europe at 5.6 (95%
CI 5.1–6.2) and 5.6 (95% CI 4.1–7.6), respectively, and
higher in South/Latin America and North America at
8.4 (95% CI 6.9–10.3) and 12.1 (95% CI 9.3–
15.7), respectively.
The ORHSV-2/HIV (Table S1 of Supplementary Informa-
tion, http://links.lww.com/QAD/B268) followed the
same regional patterns as those of RRHSV-2/HIV. There
was strong evidence for heterogeneity in both measures in
all regions. Most variation was because of heterogeneity
in effect size across studies.
Risk ratio and odds ratio by sex
The RRHSV-2/HIV for women was 5.6 (95% CI 5.1–6)
versus only 3.5 (95% CI 3.1–3.8) for men (Table 1). After
excluding SSA, the difference was even larger; 9.3 (95%
CI 8.3–10.5) for women versus 3.7 (95% CI 3.3–4.1) for
men. The RRHSV-2/HIV for women was consistently
much higher than that for men across all regions
except SSA – here the difference was minimal [3.3
(95% CI 3–3.6) for women versus 3 (95% CI 2.4–3.6) for
men].
The ORHSV-2/HIV (Table S1 of Supplementary Informa-
tion, http://links.lww.com/QAD/B268) followed the
same sex patterns as those of RRHSV-2/HIV. There was
generally strong evidence for heterogeneity in both
measures. Most variation was because of heterogeneity in
effect size across studies.
HSV-2 and HIV epidemiologic overlap Kouyoumjian et al. 1347
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Risk ratio and odds ratio by risk population and
subpopulation
The RRHSV-2/HIV in the different risk populations, both
including and excluding SSA, can be seen in Fig. 3a. The
RRHSV-2/HIV was the highest among the general
population at 5.8 (95% CI 5.4–6.3), but was comparable
among high-risk and intermediate-risk populations at 4.7
(95% CI 4.4–5.2) and 4.2 (95% CI 3.7–4.7), respectively.
After excluding SSA, the RRHSV-2/HIV was still the
highest, but much higher, among the general population
at 26.2 (95% CI 20.2–34.1), and remained comparable
among high-risk and intermediate-risk populations at 5.1
(95% CI 4.7–5.6) and 5.7 (95% CI 4.7–6.8), respectively.
The RRHSV-2/HIV in the different subpopulations of the
high-risk population can be seen in Fig. 3b. The highest
RRHSV-2/HIV was among FSWs at 6.7 (95% CI 5.9–7.5),
followed by clients of FSWs at 4.7 (95% CI 3.9–5.8), and
MSM at 2.8 (95% CI 2.6–3.2).
The ORHSV-2/HIV (Fig. S1 of Supplementary Informa-
tion, http://links.lww.com/QAD/B268) followed the
same risk population and subpopulation patterns as those
of RRHSV-2/HIV. The RRHSV-2/HIV/ORHSV-2/HIV
for the general, intermediate-risk, and high-risk popula-
tions stratified by region are shown in Table S2 of
Supplementary Information. There was generally strong
evidence for heterogeneity in both measures. Most of the
variation was because of heterogeneity in effect size
across studies.
Discussion
Through a comprehensive global analysis, we found that
there is a strong association between HSV-2 and HIV
prevalence, with HSV-2 prevalence being consistently
higher than HIV prevalence. This strong association was
evident in all world regions and all populations where
HIV is sexually transmitted. With such an association,
HSV-2 prevalence can be used as a proxy of HIV
prevalence, and could be used to predict future HIV
prevalence in a population where HIV has not yet been
introduced, or has not yet reached its epidemic potential.
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Fig. 2. Descriptive analyses of the population-level association between herpes simplex virus type 2 (HSV-2) and HIV
prevalence. Scatterplots of HIV versus HSV-2 prevalence in the following populations: (a) all datapoints; (b) female sex
workers; (c) MSM; (d) people who use drugs but do not inject; (e) people who inject drugs; (f) children; and (g) all datapoints
excluding populations where the dominantmode of HIV transmissionwas not sexual (people who inject drugs and children). The
global distribution of loge RRð Þ data (h) and loge ORð Þ data (i).
These results are consistent with these two infections
propagating in the same sexual networks and sharing
closely linked epidemiology. Indeed, no association was
found in populations where HIV’s perceived mode of
transmission was not sexual, such as for PWID and
children. These findings, based on empirical data, validate
mathematical modelling analyses that predicted similar
findings based on HIV/HSV-2 transmission simulations
[5,6].
These results imply also that HSV-2 prevalence is
effectively a ‘summary collective measure’ of the intensity
of sexual risk that drives STI transmission in a sexual
network, and accordingly HSV-2 prevalence was strongly
associated with HIV prevalence. A complementary
explanation involves an HSV-2/HIV biological interac-
tion, as suggested by earlier observational evidence [20–
23]. This seems less likely, however, with the outcomes of
clinical trials that have questioned this biological synergy
[24–26], as well as a recent mathematical modeling
analysis investigating the capacity of observational studies
to assess such biological synergy [27]. The lack of an
association we observed in PWID (Fig. 2E), despite the
possibility of some residual sexual transmission among
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Fig. 3. Meta-analyses of the pooled mean risk ratio (RRHSV-2/HIV) for herpes simplex virus type 2 (HSV-2) infection relative to
HIV infection among (a) different population groups including and excluding data from Sub-Saharan Africa, and (b) different
high-risk subpopulations.
them, further sheds doubts about the existence or scale of
an HSV-2/HIV biological synergy.
One manifestation of how HSV-2 prevalence provides a
measure of the intensity of sexual risk behavior is the
apparent threshold effect (Fig. 2b and g). In populations,
where HSV-2 prevalence was less than 20%, HIV
prevalence seemed limited or vanishing; risk-behavior
intensity was not sufficient to sustain HIV transmission,
though it could sustain (the more infectious) HSV-2
infection. In populations where HSV-2 prevalence was
greater than 20%, HIV prevalence increased steadily with
HSV-2 prevalence, as risk-behavior intensity was suffi-
cient to sustain the propagation of both infections, with
higher prevalence for both with higher risk-behavior
intensity. These findings support the modeling analyses
that predicted the existence of this threshold effect at
HSV-2 prevalence of about 20% [5,6]. Further quantita-
tive analyses are needed to investigate this apparent
threshold effect, estimate its magnitude for the different
at-risk populations, examine potential confounding
factors affecting it, and link it to the theoretical
mathematical modeling predictions [5,6].
For the global data, the RRHSV-2/HIV (that is ratio of
HSV-2 to HIV prevalence) had a value of 5 indicating
that, in average, HSV-2 prevalence was five times higher
than HIV prevalence. This ratio, however, differed by sex,
risk population/subpopulation, and region. It was much
higher for women than men (Table 1). This could be in
part explained by women being more biologically
susceptible to HSV-2 infection, and thus have higher
prevalence [28], whereas HIV is biologically equally
transmissible for both sexes [29]. The RRHSV-2/HIV for
MSM was very low (Fig. 3b), probably a consequence of
anal-sex HIV transmission probability being 10-fold
higher than that through vaginal sex [30,31], leading to a
relatively higher HIV prevalence than expected for a
heterosexual population.
Our results provide suggestive evidence that the RRHSV-
2/HIV (or ORHSV-2/HIV) may have value as ‘epidemic
diagnostics’ of the phase, sustainability, and type of HIV
epidemics circulating in a population. The RRHSV-2/HIV
was low for both SSA and for men in all regions but
MENA (Table 1). This may be explained by the
established phase of the HIV epidemics (reaching their
epidemic potential) in SSA and among MSM in most
regions, as supported by our knowledge of the global
epidemiology of HIV [32,33]. Meanwhile, the RRHSV-2/
HIV in MENA was very high, consistent with the
evidence indicating recently emerging HIV epidemics
that have not yet reached their epidemic potential
[3,4,34].
The RRHSV-2/HIV in the general population was much
lower in SSA than that in other regions (Fig. 3a). This
may be explained by the heterosexual HIV epidemics in
the general population in SSA, whereas the general-
population component of the HIV epidemic has been
weak and nonsustainable in the other regions [1,32,33].
The potential use of the RRHSV-2/HIV (or ORHSV-2/HIV)
as ‘epidemic diagnostics’ merits further investigation not
only because of the practical epidemiologic relevance, but
also because of theoretical implications about how STIs
propagate in sexual networks [6].
Our study has several limitations. The availability of data
varied by region, country, sex, and risk population/
subpopulation, thereby constraining the scope of the
analyses. Although we identified strong HSV-2/HIV
correlation, HSV-2 alone cannot explain the variation in
HIV prevalence. It has been recently suggested that there
are distinctions in how sexual networks affect each
infection transmission in a population [6]. Biological
cofactors (such as male circumcision [35,36]) can also
affect each infection differentially [37], thereby compli-
cating the association. Interventions, whether they affect
both infections (such as condom use), or one of them
(such as antiretroviral treatment) can further complicate
the association. There was heterogeneity in the RRHSV-2/
HIV (and ORHSV-2/HIV) across studies. Further work is
needed to better understand this heterogeneity and
implementation of these measures as epidemic diagnostics.
A main challenge to this approach remains that, overall,
HIV data are more abundant than HSV-2 data, as there are
no specific testing or screening programs for HSV-2.
However, there are different situations where HSV-2 data
are available and hence can be used to make predictions
about HIV future spread. This approach is especially
useful in situations where HIV prevalence is low and
where there might be lower incentive for continuous
HIV surveillance, especially in more resource-limited
settings with competing health priorities – say different
countries in Asia, most notably in India with ample HSV-
2 data [38]. In such cases, HSV-2 prevalence, if available,
can be used as a guide to whether HIV prevalence might
increase and, therefore, whether HIV monitoring and
surveillance should be prioritized. Of notice that whereas
repeated HIV surveillance surveys are needed to track the
HIVepidemic, a single HSV-2 survey may be sufficient to
assess the levels and intensity of sexual risk behavior and
HIVepidemic potential in a population – thus helping in
the prioritization of limited surveillance resources.
One example to this end is in Pakistan where surveillance
studies have been conducted among key populations at
higher risk of infection, some of which had measured the
prevalence of both HIV and HSV-2. Although in earlier
studies HIV prevalence was very limited among different
types of male sex workers, HSV-2 prevalence was
exceptionally high among transgender sex workers –
also called hijras [39], suggesting considerable HIV
epidemic potential among this male sex workers
subgroup. Indeed, repeated rounds of surveillance
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confirmed this HSV-2-based prediction where HIV
prevalence increased among hijras from 0.8% in 2005 [40]
to 1.8% in 2006 [41], and to 6.4 [42] and 5.2% [43] in
2008 and 2011, respectively, whereas it remained at about
1% among the other male sex worker subgroups who had
relatively low HSV-2 prevalence [40–43].
Conclusion
We identified and quantified a strong HSV-2/HIV
prevalence association through a systematic global
analysis. We also identified an apparent threshold effect
whereby HIV prevalence was limited below a specific
HSV-2 prevalence level. We used two measures of the
HSV-2/HIVepidemiologic overlap, and found that these
measures can potentially be used as ‘epidemic diagnostics’
of the phase, sustainability, and type of HIV epidemics.
These findings open new approaches to understand the
link between sexual risk behavior and STI transmission,
and how data on one STI can inform the epidemiology of
another STI. Further research is needed to investigate
similar associations between any two pairs of STIs, and all
of them collectively, to elucidate their overlapping
epidemiology in different population groups and
settings.
Our findings demonstrate that HSV-2 prevalence can be
used as a proxy ‘biomarker’ of HIV epidemic potential,
acting as a ‘temperature scale’ of the intensity of sexual
risk behavior that drives HIV transmission. HSV-2
prevalence can be used to identify populations and/or
sexual networks at high-risk of future HIVexpansion, and
as a criterion in the prioritization, optimization, and
resource allocation of cost-effective HIV/STI-specific
prevention interventions. These findings are of special
importance in countries (such as in MENA) with poor
surveillance systems, where the status of the HIV
epidemic remains poorly known, and where high-risk
populations are hidden and stigmatized. They also
highlight the importance and value of including HSV-
2 prevalence in integrated biobehavioral surveillance
surveys that may find vanishing HIV prevalence, as a zero
HIV prevalence does not necessarily imply no potential
for future HIV spread.
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